iCleanse Announces Collaboration with CIT to Offer Low-Interest Financing on All iCleanse Disinfection Products to Kill COVID

iCleanse www.icleanse.com, the leader in UV-C personal device disinfection, announced today that it has joined forces with CIT, a top 50 national bank, to provide low-interest financing on all iCleanse disinfection products to keep customers and staff safe from infectious pathogens.

This alliance allows iCleanse to better serve its current and future customer base, who may have limited cash flow due to the year-long pandemic, making UV-C disinfection more attainable for small and large businesses alike and keeping businesses open. iCleanse products kill 99.9% of infectious pathogens, such as COVID-19, the common cold, and influenza in as little as 15 seconds.

iCleanse’s Mission: Help Businesses Remain Safe and Open

iCleanse is the leader and only patented solution in chemical-free UV-C disinfection for mobile devices. Providing quick and effective disinfection for all types of business to help them remain safe and open is the main objective in iCleanse’s mission. Applying for financing through CIT is quick and easy, and customers can receive a decision on financing often in less than three minutes.

“Being able to offer our customers an easy financial solution to purchase our products is a no-brainer,” said Chris Allen, CEO of iCleanse. “Ensuring easy and effective disinfection of the items we use daily is one way to reduce the spread of the COVID-19 pandemic.”

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.